BTK
Gli inibitori della tirosina chinasi di Bruton (BTK) sono composti che mirano specificamente a inibire la BTK, un enzima cruciale coinvolto nella segnalazione del recettore delle cellule B e nella regolazione dell'angiogenesi. La BTK svolge un ruolo significativo nella proliferazione e nella sopravvivenza delle cellule cancerose, in particolare nelle malignità ematologiche. Inibendo la BTK, questi composti possono interrompere l'angiogenesi e la crescita tumorale, rendendoli preziosi nella terapia del cancro. Presso CymitQuimica, offriamo una gamma di inibitori della BTK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 174 prodotti per "BTK".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purezza:98%Colore e forma:SolidPeso molecolare:880.99FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Colore e forma:Odour SolidDCAF1 binder 2
DCAF1 Binder 2, an E3 ligase ligand, is implicated in BRD9, kinase, and selective Bruton's tyrosine kinase (BTK) degradation.Colore e forma:Odour SolidL18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Formula:C47H51N11O8Colore e forma:SolidPeso molecolare:897.98PCI-33380
CAS:PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.Formula:C46H52BF2N11O3Purezza:98%Colore e forma:SolidPeso molecolare:855.785DFCI-002-06
CAS:DFCI-002-06 is an orally active dual-targeted HCK/BTK PROTAC degrader, demonstrating DC₅₀ values of 1.3 nM for HCK and 4.5 nM for BTK. It retains superior antitumor activity compared to dual-targeted HCK/BTK inhibitors and induces apoptosis in cancer cells. DFCI-002-06 is applicable in studies of MYD88-mutant B-cell malignancies.Formula:C44H46N10O5Peso molecolare:794.92TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidBIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formula:C28H34N10O2Colore e forma:SolidPeso molecolare:542.6354BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Colore e forma:SolidPeso molecolare:1082.224PROTAC BTK Degrader-12
CAS:PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.Formula:C47H54N12O4Colore e forma:SolidPeso molecolare:851.01Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formula:C56H80N12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1097.39LFM-A13
CAS:LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Formula:C11H8Br2N2O2Purezza:99.50%Colore e forma:White SolidPeso molecolare:360PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formula:C43H43N9O4Colore e forma:SolidPeso molecolare:749.86DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurezza:99.94%Colore e forma:White SolidPeso molecolare:256.122PROTAC BTK Degrader-9
PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.Formula:C46H52FN13O5Colore e forma:SolidPeso molecolare:885.41984FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Colore e forma:LiquidCNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurezza:98%Colore e forma:SolidPeso molecolare:961.18PROTAC BTK Degrader-8
PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.Formula:C80H94F2N14O20P2Colore e forma:SolidPeso molecolare:1670.62121PROTAC BTK Degrader-11
CAS:PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Formula:C48H55N11O4Colore e forma:SolidPeso molecolare:850.02
